AGA1
MCID: ALP061
MIFTS: 49

Alopecia, Androgenetic, 1 (AGA1)

Categories: Rare diseases

Aliases & Classifications for Alopecia, Androgenetic, 1

MalaCards integrated aliases for Alopecia, Androgenetic, 1:

Name: Alopecia, Androgenetic, 1 56 13 37 71
Androgenetic Alopecia 56 52 25 17 71
Androgenic Alopecia 52 25
Androgenetic Alopecia; Aga 56
Female Pattern Baldness 25
Female Pattern Alopecia 71
Male Pattern Alopecia 25
Male Pattern Baldness 25
Alopecia Androgenetic 54
Pattern Baldness 25
Aga1 56
Aga 56

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant in males
recessive in females


HPO:

31
alopecia, androgenetic, 1:
Inheritance sex-limited autosomal dominant


Classifications:



External Ids:

OMIM 56 109200
OMIM Phenotypic Series 56 PS203655
MedGen 41 C4049090
SNOMED-CT via HPO 68 278040002 56317004
UMLS 71 C0162311 C0263477 C4049090

Summaries for Alopecia, Androgenetic, 1

Genetics Home Reference : 25 Androgenetic alopecia is a common form of hair loss in both men and women. In men, this condition is also known as male-pattern baldness. Hair is lost in a well-defined pattern, beginning above both temples. Over time, the hairline recedes to form a characteristic "M" shape. Hair also thins at the crown (near the top of the head), often progressing to partial or complete baldness. The pattern of hair loss in women differs from male-pattern baldness. In women, the hair becomes thinner all over the head, and the hairline does not recede. Androgenetic alopecia in women rarely leads to total baldness. Androgenetic alopecia in men has been associated with several other medical conditions including coronary heart disease and enlargement of the prostate. Additionally, prostate cancer, disorders of insulin resistance (such as diabetes and obesity), and high blood pressure (hypertension) have been related to androgenetic alopecia. In women, this form of hair loss is associated with an increased risk of polycystic ovary syndrome (PCOS). PCOS is characterized by a hormonal imbalance that can lead to irregular menstruation, acne, excess hair elsewhere on the body (hirsutism), and weight gain.

MalaCards based summary : Alopecia, Androgenetic, 1, also known as androgenetic alopecia, is related to alopecia and androgenic alopecia. An important gene associated with Alopecia, Androgenetic, 1 is AFA1 (Alopecia, Androgenetic), and among its related pathways/superpathways are Translation Non-genomic (rapid) action of Androgen Receptor and Metabolism of steroid hormones. The drugs Ethanol and Acetylcysteine have been mentioned in the context of this disorder. Affiliated tissues include prostate, ovary and skin, and related phenotypes are alopecia and endocrine/exocrine gland

NIH Rare Diseases : 52 Androgenetic alopecia is a common form of hair loss in both men and women. In men, hair is usually lost in a well-defined pattern, beginning above both temples and is usually referred to as male-pattern baldness . Over time, the hairline recedes to form a characteristic 'M' shape. Hair also thins near the top of the head, often progressing to partial or complete baldness. The pattern of hair loss in women differs from men (female pattern hair loss ). In women, the hair becomes thinner all over the head, and the hairline does not recede. Androgenetic alopecia in women rarely leads to total baldness. A variety of genetic and environmental factors likely play a role in causing this condition. Mutations in the AR gene have also been associated with androgenetic alopecia.

OMIM : 56 Androgenetic alopecia is characterized by a loss of hair from the scalp that follows a defined pattern (Hamilton, 1951). It occurs in women as well as in men. It is caused by a shortening of the anagen (growth) phase and miniaturization of the hair follicle, which results in the formation of progressively thinner, shorter hair (Bergfeld, 1995). In men, the condition is often referred to as male pattern baldness (MPB) and appears to be androgen-dependent (Hamilton, 1942). The condition is hereditary, and follows a pattern that may be consistent with an autosomal dominant trait (Osborn, 1916). Linkage evidence for an autosomal locus on 3q26 (AGA1) has been identified (Hillmer et al., 2008). See 300710 (AGA2) for a discussion of X linkage of androgenetic alopecia. A third locus has been found on chromosome 20p11 (AGA3; 612421). (109200)

Related Diseases for Alopecia, Androgenetic, 1

Diseases in the Alopecia, Androgenetic, 1 family:

Alopecia, Androgenetic, 2 Alopecia, Androgenetic, 3

Diseases related to Alopecia, Androgenetic, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 375)
# Related Disease Score Top Affiliating Genes
1 alopecia 31.9 SRD5A2 SRD5A1 SHBG AR
2 androgenic alopecia 31.8 TGFB2 SRD5A2 SRD5A1 SHBG CYP19A1 AR
3 impotence 31.0 SRD5A1 SHBG AR
4 hair disease 30.5 SRD5A2 SHBG AR
5 prostatic hyperplasia, benign 30.5 SRD5A2 SRD5A1 SHBG AR
6 prostatic hypertrophy 30.0 SRD5A2 SRD5A1 SHBG CYP19A1 AR
7 hyperandrogenism 29.8 SRD5A1 SHBG CYP21A2 CYP19A1 AR
8 prostate disease 29.7 SRD5A2 SRD5A1 CYP19A1 AR
9 hypogonadism 29.7 SHBG CYP19A1 AR
10 premature ovarian failure 1 29.7 SHBG CYP19A1 AR
11 lipoid congenital adrenal hyperplasia 29.6 SRD5A1 SHBG CYP21A2 CYP19A1
12 polycystic ovary syndrome 29.6 SRD5A1 SHBG CYP21A2 CYP19A1 AR
13 male infertility 29.4 SHBG CYP21A2 CYP19A1 AR
14 gynecomastia 28.9 SRD5A2 SRD5A1 SHBG CYP21A2 CYP19A1 AR
15 endometrial cancer 28.3 STS SHBG CYP19A1 CFLAR AR
16 prostate cancer 27.5 XIAP TGFB2 SRD5A2 SRD5A1 SHBG CYP19A1
17 aspartylglucosaminuria 12.7
18 marie unna congenital hypotrichosis 11.5
19 lysosomal storage disease 11.5
20 hypotrichosis 1 11.4
21 hypotrichosis simplex 11.4
22 fabry disease 11.3
23 angiokeratoma 11.3
24 glucocorticoid resistance, generalized 11.3
25 contractural arachnodactyly, congenital 11.2
26 loeys-dietz syndrome 11.2
27 distal arthrogryposis 11.2
28 muscular disease 11.2
29 muscle tissue disease 11.2
30 lysosomal disease 11.2
31 rapidly involuting congenital hemangioma 10.9
32 alopecia areata 10.8
33 neurofibromatosis, type ii 10.7
34 telogen effluvium 10.7
35 sexual disorder 10.6
36 prostatic adenoma 10.6
37 frontal fibrosing alopecia 10.5
38 lipid metabolism disorder 10.4
39 arteries, anomalies of 10.3
40 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.3
41 hyperlipoproteinemia, type iii 10.3
42 lipoprotein quantitative trait locus 10.3
43 diffuse alopecia areata 10.3
44 urolithiasis 10.3
45 infant gynecomastia 10.3
46 contact dermatitis 10.3
47 skin disease 10.3
48 seborrheic dermatitis 10.3
49 inflammatory bowel disease 10.3
50 celiac disease 1 10.3

Graphical network of the top 20 diseases related to Alopecia, Androgenetic, 1:



Diseases related to Alopecia, Androgenetic, 1

Symptoms & Phenotypes for Alopecia, Androgenetic, 1

Human phenotypes related to Alopecia, Androgenetic, 1:

31
# Description HPO Frequency HPO Source Accession
1 alopecia 31 HP:0001596

Symptoms via clinical synopsis from OMIM:

56
Hair:
early baldness

Clinical features from OMIM:

109200

MGI Mouse Phenotypes related to Alopecia, Androgenetic, 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.17 AR CFLAR CYP19A1 SRD5A1 SRD5A2 TGFB2

Drugs & Therapeutics for Alopecia, Androgenetic, 1

Drugs for Alopecia, Androgenetic, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
3
Histamine Approved, Investigational Phase 4 51-45-6 774
4
Cetirizine Approved Phase 4 83881-51-0 2678
5
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
6 Anti-Infective Agents Phase 4
7 Anti-Infective Agents, Local Phase 4
8 Fenugreek Phase 4
9 Fenugreek seed meal Phase 4
10 N-monoacetylcystine Phase 4
11 Histamine Antagonists Phase 4
12 Histamine H1 Antagonists, Non-Sedating Phase 4
13 Anti-Allergic Agents Phase 4
14 Histamine H1 Antagonists Phase 4
15
Histamine Phosphate Phase 4 51-74-1 65513
16 Neurotransmitter Agents Phase 4
17
Dutasteride Approved, Investigational Phase 3 164656-23-9 152945 6918296
18
Zinc Approved, Investigational Phase 1, Phase 2 7440-66-6 32051
19
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
20
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
21
Bimatoprost Approved, Investigational Phase 2 155206-00-1 5311027
22
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
23
Vitamin C Approved, Nutraceutical Phase 1, Phase 2 50-81-7 5785 54670067
24
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-17-8, 110-16-7 444972
25 Trace Elements Phase 1, Phase 2
26 Nutrients Phase 1, Phase 2
27 Micronutrients Phase 1, Phase 2
28 Adjuvants, Immunologic Phase 2
29 Protective Agents Phase 2
30 Radiation-Protective Agents Phase 2
31 Antiviral Agents Phase 2
32 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 2
33 Chelating Agents Phase 1, Phase 2
34 Zinc Supplement Phase 1, Phase 2
35 Respiratory System Agents Phase 1, Phase 2
36 Antioxidants Phase 1, Phase 2
37 Anti-Asthmatic Agents Phase 1, Phase 2
38 Endothelium-Dependent Relaxing Factors Phase 1, Phase 2
39 Bronchodilator Agents Phase 1, Phase 2
40 abobotulinumtoxinA Phase 2
41 Cholinergic Agents Phase 2
42 Botulinum Toxins Phase 2
43 Botulinum Toxins, Type A Phase 2
44
protease inhibitors Phase 2
45 HIV Protease Inhibitors Phase 2
46 Proteasome Inhibitors Phase 2
47 Androgens Phase 2
48 Ophthalmic Solutions Phase 2
49 Psychotropic Drugs Phase 2
50 Anticonvulsants Phase 2

Interventional clinical trials:

(show top 50) (show all 133)
# Name Status NCT ID Phase Drugs
1 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
2 Minoxidil in Treatment of Androgenetic Alopecia Completed NCT04090801 Phase 4 Topical minoxidil 5% in 90% ethanol and 5% propylene glycol;Topical minoxidil 5% in pure ethanol alone
3 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
4 Efficacy and Tolerability of N-Acetyl- Cysteine for Treatment of The Early-onset Androgenetic Alopecia in Men Recruiting NCT04209803 Phase 4 Minoxidil 5% topically and oral NAC 600 mg
5 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Recruiting NCT03388840 Phase 4
6 Topical Cetirizine Gel Versus Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Not yet recruiting NCT04293822 Phase 4 Cetirizine;Minoxidil
7 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
8 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
9 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
10 Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study Completed NCT03753113 Phase 3 Topical Herbal Solution;Topical Minoxidil 5%
11 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
12 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
13 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
14 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
15 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
16 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
17 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
18 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
19 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
20 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
21 A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males Completed NCT00151515 Phase 3 minoxidil
22 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia Active, not recruiting NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical SM04554 solution;Topical vehicle solution
23 H-36371: Finasteride as a Method of Managing Testosterone-Induced Erythrocytosis Withdrawn NCT02548117 Phase 3 Finasteride
24 A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Unknown status NCT00471510 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
25 The Clinical Effects of HSC (Hair Stimulating Complex) on Hair Growth in Androgenetic Alopecia: A Phase I/II Clinical Trial Unknown status NCT01501617 Phase 1, Phase 2
26 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA) Unknown status NCT01643629 Phase 1, Phase 2
27 An Efficacy and Safety Pilot Study Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Treatment of AGA Unknown status NCT01650272 Phase 1, Phase 2 5% MInoxidil milky lotion;5% Minoxidil solution
28 Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women Unknown status NCT00418249 Phase 2 AS101
29 A Multi-center, Randomized, Controlled, Double-blind Study That Evaluates a Low Level Laser Therapy Over-the-counter at Home Device, Theradome™ LH80 PRO vs a Sham Device, for Promoting Hair Growth in Males Diagnosed With Androgenetic Alopecia Unknown status NCT02528552 Phase 2
30 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate Safety & Efficacy Of Autologous Human Platelet Lysate For Treatment Of Androgenetic Alopecia In Patients Undergoing Hair Transplant Unknown status NCT01644422 Phase 1, Phase 2
31 A Pilot Study of the Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Oral Chelated Zinc Supplement Unknown status NCT01662089 Phase 1, Phase 2 15 mg Chelate zinc supplement;Placebo drug supplement
32 Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia Unknown status NCT01347957 Phase 1, Phase 2
33 A Randomised, Double-blind, Placebo-controlled Phase 2 Trial of FOL-005 to Investigate Efficacy on Hair Growth on Scalp Skin in Healthy Volunteers Unknown status NCT03467412 Phase 2 FOL-005;Placebo
34 A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing Completed NCT02503137 Phase 2 Topical SM04554 solution;Topical Vehicle solution
35 A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of ex Vivo-cultured, Expanded, Occipital Autologous Dermal and Epidermal Cells, Injected Into the Hair Loss Area of the Scalp of Male and Female Subjects With Alopecia Completed NCT01669746 Phase 2
36 A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451190 Phase 2
37 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells, Where Cells Are Expanded ex Vivo From Plucked Scalp, Into the Hair Loss Area of the Scalp of Subjects. Completed NCT01451177 Phase 2
38 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451151 Phase 2
39 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451138 Phase 2
40 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects and Synergy With Application of Topical Minoxidil Completed NCT01451125 Phase 2
41 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451112 Phase 2
42 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451099 Phase 2
43 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Same Day as Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451073 Phase 2
44 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451047 Phase 2
45 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Day After Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451021 Phase 2
46 A Prospective, Single Center, Open Label, Proof of Principle Study to Assess the Efficacy and Safety of 150 Units of Botulinum Toxin-A Intra-Muscular Injection in the Prevention of Hair Loss in Men With Androgenetic Alopecia Completed NCT00965640 Phase 2 Botulinum Toxin - A injections
47 A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Completed NCT00418730 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
48 A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA) Completed NCT02279823 Phase 2 CB-03-01 solution;Minoxidil Solution 5%;Placebo solution
49 A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Completed NCT02275351 Phase 2 SM04554;Vehicle
50 Randomized, Single-centre, Double-blind, Placebo-controlled, Phase I / IIa Study to Evaluate the Safety and Efficacy of Human Autologous Hair Follicle Dermal Sheath Cup Cells (DSCC) in Women and Men With Androgenetic Alopecia. Completed NCT01286649 Phase 1, Phase 2

Search NIH Clinical Center for Alopecia, Androgenetic, 1

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Alopecia, Androgenetic, 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Alopecia, Androgenetic, 1:
RepliCel Hair-01 (RCH-01), hair follicle-derived mesenchymal stem cells for treatment of androgenetic alopecia
Embryonic/Adult Cultured Cells Related to Alopecia, Androgenetic, 1:
Hair follicle mesenchymal stem cells (RepliCel Hair-01)

Genetic Tests for Alopecia, Androgenetic, 1

Anatomical Context for Alopecia, Androgenetic, 1

MalaCards organs/tissues related to Alopecia, Androgenetic, 1:

40
Prostate, Ovary, Skin, Heart, Testes, Breast, Endothelial

Publications for Alopecia, Androgenetic, 1

Articles related to Alopecia, Androgenetic, 1:

(show top 50) (show all 1455)
# Title Authors PMID Year
1
Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. 56 61
18304493 2008
2
The hairless gene in androgenetic alopecia: results of a systematic mutation screening and a family-based association approach. 56 61
11966690 2002
3
Androgenetic alopecia in heterozygous carriers of a mutation in the human hairless gene. 56 61
10827399 2000
4
The inheritance of common baldness: two B or not two B? 56 61
6512048 1984
5
Genetic analysis of male pattern baldness and the 5alpha-reductase genes. 56
9620288 1998
6
Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. 56
7849715 1994
7
Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. 56
8334753 1993
8
Patterned loss of hair in man; types and incidence. 56
14819896 1951
9
Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity. 61 54
19663790 2009
10
Recent positive selection of a human androgen receptor/ectodysplasin A2 receptor haplotype and its relationship to male pattern baldness. 54 61
19373488 2009
11
Evaluation of androgen receptor gene as a candidate gene in female androgenetic alopecia. 54 61
19538365 2009
12
Androgen receptor copy number variation and androgenetic alopecia: a case-control study. 61 54
19340294 2009
13
Finasteride treatment and neuroactive steroid formation. 54 61
19655698 2009
14
Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old. 61 54
18363752 2008
15
Men with Kennedy disease have a reduced risk of androgenetic alopecia. 61 54
17596176 2007
16
Baldness and the androgen receptor: the AR polyglycine repeat polymorphism does not confer susceptibility to androgenetic alopecia. 61 54
17256155 2007
17
[Premature androgenetic alopecia in adult male with nonclassic 21-OH deficiency. A novel nonsense CYP21A2 mutation (Y336X) in 2 affected siblings]. 61 54
17145028 2006
18
A new look at the 5alpha-reductase inhibitor finasteride. 61 54
16834758 2006
19
The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. 61 54
15824176 2005
20
Solubilization and solid-state characterization of a poorly soluble 5-alpha reductase inhibitor. 61 54
15285330 2004
21
Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. 61 54
14729013 2004
22
Testosterone metabolism in human skin cells in vitro and its interaction with estradiol and dutasteride. 54 61
14528059 2003
23
Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia. 61 54
12670724 2003
24
Male-pattern baldness is common in men with X-linked recessive ichthyosis. 54 61
14571075 2003
25
Acne: effect of hormones on pathogenesis and management. 61 54
12358558 2002
26
Steroid sulfatase in the human hair follicle concentrates in the dermal papilla. 61 54
11886493 2001
27
Androgen responsive genes as they affect hair growth. 61 54
11399535 2001
28
The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. 61 54
11125319 2000
29
[Hormonal profile in men with premature androgenic alopecia]. 54 61
10953626 2000
30
[Treatment of androgenetic alopecia in the man using systemic 5 alpha-reductase inhibition]. 61 54
9879479 1998
31
Delayed telogen replacement in a boy's scalp. 54 61
9873170 1998
32
Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. 54 61
9284093 1997
33
Hormonal status in postmenopausal androgenetic alopecia. 61 54
1478763 1992
34
A comprehensive review of biochemical factors in herbs and their constituent compounds in experimental studies on alopecia. 61
32360043 2020
35
Accelerated hair growth by combining thread monofilament and minoxidil in female androgenetic alopecia. 61
31789457 2020
36
Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19? 61
32333494 2020
37
Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm. 61
32202088 2020
38
Correction to: Comparative Study to Evaluate Tolerability of Topical 5% Minoxidil Novel Formulation and Alcohol-Based Conventional Solutions in Treatment of Androgenetic Alopecia in Indian Men: Randomized Double-Blind Study. 61
32350810 2020
39
Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway. 61
32412314 2020
40
Comparative Study to Evaluate Tolerability of Topical 5% Minoxidil Novel Formulation and Alcohol-Based Conventional Solutions in Treatment of Androgenetic Alopecia in Indian Men: Randomized Double-Blind Study. 61
32277388 2020
41
Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. 61
32538225 2020
42
The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis. 61
32166351 2020
43
Favorable effects of microneedling on long-standing androgenetic alopecia in an elderly man: A case report. 61
32500595 2020
44
Androgenetic alopecia: effects of oral finasteride on hormone profile, reproduction and sexual function. 61
32052367 2020
45
The effectiveness of combination therapies for androgenetic alopecia: A systematic review and meta-analysis. 61
32478968 2020
46
Clinical experience on follicular unit extraction megasession for severe androgenetic alopecia. 61
31529675 2020
47
Cross Sectional Quality of Life Assessment in Patients with Androgenetic Alopecia. 61
32520416 2020
48
Study of serum vitamin D levels in men with premature androgenetic alopecia. 61
32516435 2020
49
Evaluation of quality of life of patients with hirsutism among Turkish women: A single-center cross-sectional study. 61
32564506 2020
50
Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. 61
32571540 2020

Variations for Alopecia, Androgenetic, 1

Expression for Alopecia, Androgenetic, 1

Search GEO for disease gene expression data for Alopecia, Androgenetic, 1.

Pathways for Alopecia, Androgenetic, 1

GO Terms for Alopecia, Androgenetic, 1

Cellular components related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum membrane GO:0005789 9.55 STS SRD5A2 SRD5A1 CYP21A2 CYP19A1
2 intracellular membrane-bounded organelle GO:0043231 9.35 STS SRD5A2 SRD5A1 CYP21A2 CYP19A1
3 organelle membrane GO:0031090 8.92 SRD5A2 SRD5A1 CYP21A2 CYP19A1

Biological processes related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.58 CFLAR AR
2 cellular response to estradiol stimulus GO:0071392 9.58 SRD5A1 CFLAR
3 response to testosterone GO:0033574 9.57 SRD5A1 CFLAR
4 cellular response to dexamethasone stimulus GO:0071549 9.56 SRD5A1 CFLAR
5 steroid metabolic process GO:0008202 9.56 STS SRD5A2 SRD5A1 CYP21A2
6 sterol metabolic process GO:0016125 9.55 CYP21A2 CYP19A1
7 sex differentiation GO:0007548 9.54 SRD5A2 SRD5A1
8 male genitalia development GO:0030539 9.52 SRD5A2 SRD5A1
9 uterus development GO:0060065 9.51 TGFB2 CYP19A1
10 androgen biosynthetic process GO:0006702 9.49 SRD5A2 SRD5A1
11 cellular response to testosterone stimulus GO:0071394 9.48 SRD5A1 AR
12 prostate gland growth GO:0060736 9.46 CYP19A1 AR
13 male gonad development GO:0008584 9.46 TGFB2 SRD5A2 SRD5A1 AR
14 testosterone biosynthetic process GO:0061370 9.43 SRD5A2 CYP19A1
15 female genitalia development GO:0030540 9.4 SRD5A1 CYP19A1
16 androgen catabolic process GO:0006710 9.37 SRD5A1 CYP19A1
17 positive regulation of integrin biosynthetic process GO:0045726 9.32 TGFB2 AR
18 androgen metabolic process GO:0008209 9.13 SRD5A2 SRD5A1 CYP19A1
19 steroid biosynthetic process GO:0006694 8.92 SRD5A2 SRD5A1 CYP21A2 CYP19A1

Molecular functions related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.71 SRD5A2 SRD5A1 CYP21A2 CYP19A1
2 steroid hydroxylase activity GO:0008395 9.37 CYP21A2 CYP19A1
3 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.32 SRD5A2 SRD5A1
4 androgen binding GO:0005497 9.26 SHBG AR
5 cholestenone 5-alpha-reductase activity GO:0047751 9.16 SRD5A2 SRD5A1
6 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 8.96 SRD5A2 SRD5A1
7 steroid binding GO:0005496 8.8 SHBG CYP21A2 AR

Sources for Alopecia, Androgenetic, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....